DXCM vs TNDM Stock Comparison: AI Score, Valuation, Performance and Upside
DXCM and TNDM are complementary diabetes technology companies whose devices integrate to create closed-loop automated insulin delivery systems. Dexcom provides the glucose sensing, while Tandem provides the insulin pump with the Control-IQ algorithm that acts on Dexcom's data. Dexcom is the larger, faster-growing platform while Tandem faces more competitive pressure in insulin pumps.
DXCM vs TNDM covers complementary diabetes technology platforms — Dexcom's glucose sensor leadership and massive Type 2 expansion opportunity against Tandem's AID insulin pump competing in a smaller but clinically important market.
DXCM holds the edge across 4 of 5 key metrics in this comparison. DXCM leads on both 1-year return (+45.59%) and forward P/E quality (29.07x vs 120.45x for TNDM), a relatively favorable combination of momentum and valuation. DXCM leads on both revenue growth (13.10%) and operating margin (24.33%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for TNDM (+39.59%) than for DXCM (+3.63%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want the leading CGM platform with established Type 1 dominance and a massive Type 2 expansion opportunity ahead
- Value Dexcom's G7 technology upgrade as improving competitive positioning versus Abbott FreeStyle Libre
- See CGM adoption in the broader diabetes population (not just insulin-dependent) as a decades-long growth runway
- Want insulin pump technology exposure with an automated insulin delivery (AID) system respected by endocrinologists and patients
- Value Tandem's Control-IQ algorithm clinical performance and software update capability as technology differentiators
- See Mobi launch as expanding Tandem's addressable market into the tubeless patch pump segment
| Metric | DXCM | TNDM |
|---|---|---|
| AI scorei | 52.3 | 26.0 |
| AI ranki | #250 | #2571 |
| Latest closei | $84.76 | $18.67 |
| 1M returni | -0.70% | +13.15% |
| 3M returni | -2.92% | -7.16% |
| 6M returni | +41.17% | -6.04% |
| 1Y returni | +45.59% | +33.36% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DXCM | TNDM |
|---|---|---|
| 1Y ago | $14.03K (+40.3%) started 2025-11-03 | $13K (+30.0%) started 2025-11-03 |
| 5Y ago | $5.47K (-45.3%) started 2021-11-03 | $1.32K (-86.8%) started 2021-11-03 |
| 10Y ago | $56.43K (+464.3%) started 2016-11-03 | $9.57K (-4.3%) started 2016-11-03 |
Hypothetical — past performance does not guarantee future results.
| Metric | DXCM | TNDM |
|---|---|---|
| Market capi | $34.27B | $1.43B |
| Trailing P/Ei | 35.90 | N/A |
| Forward P/Ei | 29.07 | 120.45 |
| Price/Salesi | 8.19 | N/A |
| EV/Revenuei | 6.79 | 1.69 |
| Analyst targeti | $94.12 | $28.70 |
| Target upsidei | +3.63% | +39.59% |
| Metric | DXCM | TNDM |
|---|---|---|
| Revenue growthi | 13.10% | 5.80% |
| Earnings growthi | 43.60% | N/A |
| EPS growthi | +43.60% | N/A |
| FCF margini | +20.55% | -4.22% |
| Operating margini | 24.33% | -5.42% |
| Profit margini | 20.12% | -6.08% |
| ROIC proxyi | 38.49% | -48.03% |
| Return on equityi | 38.49% | -48.03% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.41 | 1.54 |
| Debt/equityi | 53.35 | 566.96 |
| Current ratioi | 1.73 | 3.18 |
| Quick ratioi | 1.37 | 2.44 |
Over the past year, DXCM and TNDM have moved weakly in the same direction (correlation of 0.27), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | DXCM | TNDM |
|---|---|---|---|
| 1Y | Growthi | +40.26% | +30.01% |
| CAGRi | +40.41% | +30.13% | |
| Volatilityi | 37.79% | 77.02% | |
| Sharpe ratioi | 0.97 | 0.65 | |
| Sortino ratioi | 1.58 | 1.14 | |
| Max drawdowni | 22.61% | 54.64% | |
| Current drawdowni | 8.21% | 33.93% | |
| Avg drawdowni | 6.51% | 25.72% | |
| Ulcer Indexi | 8.66% | 30.04% | |
| Max daily dropi | 6.39% | 16.19% | |
| Max wkly dropi | 10.71% | 25.67% | |
| 5Y | Growthi | -45.29% | -86.80% |
| CAGRi | -11.37% | -33.32% | |
| Volatilityi | 47.31% | 69.16% | |
| Sharpe ratioi | -0.10 | -0.30 | |
| Sortino ratioi | -0.14 | -0.44 | |
| Max drawdowni | 66.32% | 93.40% | |
| Current drawdowni | 47.94% | 87.81% | |
| Avg drawdowni | 41.72% | 73.74% | |
| Ulcer Indexi | 44.23% | 76.61% | |
| Max daily dropi | 40.66% | 35.25% | |
| Max wkly dropi | 42.68% | 43.11% | |
| 10Y | Growthi | +464.31% | -4.26% |
| CAGRi | +18.90% | -0.43% | |
| Volatilityi | 48.41% | 75.59% | |
| Sharpe ratioi | 0.51 | 0.31 | |
| Sortino ratioi | 0.74 | 0.46 | |
| Max drawdowni | 66.32% | 93.40% | |
| Current drawdowni | 47.94% | 87.81% | |
| Avg drawdowni | 27.05% | 51.85% | |
| Ulcer Indexi | 33.38% | 61.60% | |
| Max daily dropi | 40.66% | 36.11% | |
| Max wkly dropi | 42.68% | 63.54% |
| Category | DXCM | TNDM |
|---|---|---|
| Company | DexCom, Inc. | Tandem Diabetes Care, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | Dexcom designs and markets wearable continuous glucose monitoring (CGM) systems that measure blood glucose levels in real time using a small sensor worn on the body, providing real-time readings and trend alerts to patients and caregivers without fingerstick blood tests. | Tandem Diabetes Care develops t:slim X2 insulin pumps with the Control-IQ closed-loop automated insulin delivery (AID) algorithm, integrating with CGM sensors (including Dexcom) to automatically adjust basal insulin delivery to maintain glucose in range. |
| Investor focus | Investors track Dexcom's revenue growth in Type 1 and Type 2 diabetes users, expansion into Type 2 non-insulin users (a massive untapped market), G7 sensor adoption driving ASP improvements, and global market expansion. | Investors track Tandem's new pump shipments, installed base growth, Control-IQ international adoption, Mobi tubeless pump launch traction, and the company's revenue per unit and path toward profitability. |
- CGM has become the standard of care for Type 1 diabetes management — Dexcom is the leading CGM provider with the most clinically validated system
- G7 is a smaller, more accurate, more comfortable sensor than predecessors, improving competitive positioning versus Abbott FreeStyle Libre
- Type 2 diabetes expansion represents a massive market opportunity — hundreds of millions of Type 2 patients globally could benefit from CGM
- Control-IQ AID algorithm is highly regarded by endocrinologists and patients for its clinical performance in maintaining time-in-range glucose control
- Tandem's t:connect app and software update capability (over-the-air pump updates) provide a technology differentiation in the insulin pump market
- Mobi launch addresses the tubeless patch pump market segment dominated by Insulet's Omnipod
- Abbott FreeStyle Libre is a strong, lower-cost CGM competitor that has gained significant market share globally and threatens Dexcom in Type 2 expansion
- CGM sensor pricing faces ongoing reimbursement pressure from payers and potential commoditization risk as technology matures
- Manufacturing scale-up for the large Type 2 market opportunity requires significant capital investment
- Insulet's Omnipod DASH and Omnipod 5 tubeless AID system compete directly for users who prefer patch pumps over traditional tubed pumps
- Pump market is maturing and requires ongoing technology differentiation to sustain new customer growth
- Competition from Abbott and Medtronic integrated systems could reduce Tandem's CGM integration flexibility advantage
Compare more than two at a time
This page is a fixed writeup on DXCM and TNDM. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside DXCM and TNDM, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.